Horn corals of the species Antillogorgia elisabethae produce antibiotic natural substances. A research team at TUM has successfully produced one of these substances in the laboratory.
Image: Thomas Brück / TUM
Sustainable biotechnological production of a natural substance against tuberculosis
Natural antibiotic from the biotechnological laboratory
Together with his team at the Werner Siemens Chair of Synthetic Biotechnology, he has now managed for the first time to produce one of the sea whip’s active agents in the laboratory – without the need for a single reef inhabitant. The molecule “erogorgiaene” is an antibiotic. Initial bioactivity tests show, that it is suitable for fighting multi-resistant tuberculosis pathogens.
Previously, a use of the active agent was almost unthinkable: The sea whip contains only extremely small quantities of erogorgiaene and is additionally protected – using it as a raw material source would be neither financially feasible nor ecologically responsible. Although production via conventional chemical synthesis is possible, it is complex and associated with toxic waste. A kilo of the active agent would cost around EUR 21,000.
Sustainable biotechnology reduces the production costs
“However, with biotechnological methods, a consolidated erogorgiaene production is feasible, in a more environmentally friendly manner and much cheaper. With this method, the production costs per kilo would only be around EUR 9,000,” emphasizes Brück.
The new method, which he has developed together with colleagues from Berlin, Canada, and Australia, consists of only two steps: The main work is done by genetically optimized bacteria that feed on glycerin – a residual substance from biodiesel production.
The bacteria generate a molecule, that can then be converted into the desired active agent using a highly selective enzymatic step. No waste is produced in the process, as all ancillary products can be reused in a circular manner. A patent has been filed for the innovative production method.
Bioactive product development along the lines of nature
“The new technology platform for the production of bioactive natural products via biotechnological methodologies complies with all 12 criteria of Green Chemistry,” says Thomas Brück. “In addition, it fulfills four of the UN Sustainability Goals: a healthy life for all, combating climate change and its effects, preservation and sustainable use of the oceans and maritime resources, and preservation of life on land.”
The research team is now working on the biotechnological production of another coral active agent: Using nature as a model, the molecule erogorgiaene is to be converted into the active agent pseudopteropsin in the laboratory.
Medical professionals are placing great hope on the latter: Clinical studies have shown that pseudopteropsin inhibits inflammations thanks to a new mechanism of action. Thus, it is a potential therapeutic candidate to control excessive inflammatory reactions, for example in the case of viral infections, such as Covid-19, or during age-related chronic inflammations.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Feed has no items.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Coronavirus Update: Tuberculosis vaccine being tested in Canada for effectiveness against COVID-19on October 6, 2020 at 4:41 pm
Donald Trump continues to play down severity of virus while still infected; First antigen rapid test for COVID-19 approved by Health Canada ...
- Prisoner contracts tuberculosison October 6, 2020 at 10:56 am
"Unfortunately, medical information is not readily given out to staff, and it's a concern of ours that somebody comes in with something transferrable via the atmosphere, and we don't know about it ...
- Canadian researchers begin clinical trials of tuberculosis vaccine for COVID-19on October 6, 2020 at 7:09 am
Researchers in Canada are hoping a century-old vaccine designed to treat tuberculosis can become the key to fighting off a COVID-19 infection.
- Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosison October 6, 2020 at 6:14 am
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule ...
- Health and safety review under way after Tuberculosis case in Waikato prisonon October 5, 2020 at 9:37 pm
There is at least one case of tuberculosis, known as TB, in the Spring Hill prison in North Waikato. Spring Hill Prison director Megan Tuhoro said the secure and controlled nature of the prison ...